Clinical Trials

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT01575548 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

129 enrolled 11 charts

Carcinoma, Renal Cell

NCT01946204 2026-04-13

SPARTAN

1,207 enrolled 15 charts 2 FDA

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 2 FDA

Prostatic Neoplasms

NCT03055013 2026-04-13

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 3 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT05678322 2026-03-25

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

26 enrolled 7 charts

Prostatic Neoplasms

NCT04689828 2026-03-23

PSMAfore

469 enrolled 11 charts 3 FDA

Prostatic Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT00379340 2026-03-17

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

395 enrolled 15 charts

Wilms Tumor

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

296 enrolled 29 charts

Prostate Adenocarcinoma

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT03142334 2026-03-10

KEYNOTE-564

994 enrolled 10 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT00936390 2026-03-06

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

1,538 enrolled 37 charts

Prostatic Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

239 enrolled 38 charts

Prostatic Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT00063882 2026-03-05

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

588 enrolled 34 charts

Prostatic Neoplasms

NCT04736199 2026-02-27

ARANOTE

669 enrolled 16 charts

Prostatic Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT00352534 2026-02-18

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

808 enrolled 11 charts

Wilms Tumor

NCT03898180 2026-02-05

LEAP-011

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 2 FDA

Carcinoma, Renal Cell

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

895 enrolled 19 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT04165317 2026-01-22

CREST

1,068 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT01809691 2025-12-31

S1216

1,313 enrolled 22 charts

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT00309985 2025-12-11

CHAARTED

790 enrolled 11 charts

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

1,306 enrolled 25 charts 5 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

395 enrolled 25 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 2 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT04838613 2025-10-20

GuidePath

190 enrolled 25 charts

Prostatic Neoplasms, Recurrence

NCT04186845 2025-09-22

Spotlight

391 enrolled 30 charts

Disease, Prostatic Neoplasms

NCT01120249 2025-09-16

S0931

1,545 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04149574 2025-09-16

CheckMate 7G8

Phase 3 Terminated

13 enrolled 11 charts

Urinary Bladder Neoplasms

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT05590793 2025-09-09

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

195 enrolled 19 charts

Prostatic Neoplasms

NCT03374488 2025-08-22

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

84 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

886 enrolled 37 charts 2 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

129 enrolled 13 charts